-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lymphoma is one of the ten most common malignant tumors in China
.
According to statistics from the World Health Organization, the annual growth rate of lymphoma is 7.
5%, and it is currently one of the fastest-growing malignant tumors.
There are approximately 350,000 new cases worldwide each year
.
September 15, 2021 is the 18th "World Lymphoma Awareness Day"
.
On this occasion, Yimaitong had the honor to invite Professor Zhu Jun from Peking University Cancer Hospital to share the status quo and future development of lymphoma diagnosis and treatment in China
.
Yimaitong: Today we have ushered in the 18th "World Lymphoma Awareness Day".
What do you think of the rapid development of lymphoma diagnosis and treatment in my country in the past 18 years? Professor Zhu Jun has made great progress in the diagnosis and treatment of lymphoma in China in the past 18 years
.
First of all, clinicians in China have greatly improved their awareness of lymphoma, and standardized diagnosis and treatment have also been promoted nationwide
.
In the past, our understanding of different types of lymphomas was still lacking, but now with the widespread application of the internationally accepted WHO classification in the diagnosis of lymphomas, the misdiagnosis rate of lymphoma patients in China has been significantly improved
.
Secondly, the efficacy of lymphoma patients in China has also been greatly improved in the past 18 years
.
Taking the Lymphoma Department of Peking University Cancer Hospital as an example, the 5-year overall survival rate of lymphoma patients has increased by about 10%-15% in the past 18 years
.
At present, the 5-year overall survival rate of lymphoma patients in our department can reach more than 60%, and the 5-year overall survival rate of patients with classic Hodgkin’s lymphoma can reach 82%
.
This shows that the diagnosis and treatment level of lymphoma in China has improved significantly in the past 18 years
.
However, due to China's vast territory and uneven development in various regions, the 5-year overall survival rate of lymphoma patients nationwide is still at a low level in the world
.
To achieve the goal of cancer control in "Healthy China 2030", we need to increase the 5-year overall survival rate of lymphoma patients by at least 15% by 2030
.
This is both a pressure and a motivation
.
At present, there is still much room for improvement in the overall diagnosis and treatment of lymphoma in China.
The key to improving the diagnosis and treatment of lymphoma is to promote standardized diagnosis and treatment of lymphoma nationwide, strengthen multidisciplinary cooperation, and promote the development of lymphoma specialization.
Patients with multiple lymphomas can receive full health management and achieve an increase in the cure rate of lymphomas
.
Therefore, if we want to improve the 5-year overall survival of lymphoma patients, we still have a lot of work to do
.
Yimaitong: At present, China has made a lot of progress in the field of oncology
.
In order to further promote the development of standardized diagnosis and treatment of lymphoma, to achieve a 15% increase in the overall cancer 5-year survival rate as soon as possible, and to promote the implementation of the "Healthy China 2030 Plan", what actions or plans are currently in place? Do you have any suggestions for further planning in the future? Professor Zhu Jun First of all, I will start from myself, from our department and our center
.
By strengthening the standardized diagnosis and treatment of lymphoma and multidisciplinary cooperation, the lymphoma specialist team can develop better
.
Secondly, we also need to play the role of demonstration and lead, and better unite with colleagues across the country to promote standardized diagnosis and treatment of lymphoma and multidisciplinary cooperation
.
At present, the CSCO Anti-Lymphoma Expert Committee is an important platform.
We need to use this platform together with other different industry platforms across the country to help our colleagues across the country gain more relevant academic knowledge, so as to better promote the standardized diagnosis and treatment of lymphoma.
Disciplinary cooperation
.
Finally, at the level of national industry guidance, the expert committee established by us and the National Health Commission also needs to further promote the construction of lymphoma specialization across the country, improve the academic level of the specialized team, and promote it through more exchanges and learning.
Standardized diagnosis and treatment of lymphoma
.
I believe that as long as our colleagues across the country work together and work towards the goal of standardized diagnosis and treatment of lymphoma, we will definitely make substantial progress
.
Yimaitong: More than 20 years ago, the appearance of CD20 monoclonal antibody changed the treatment pattern of lymphoma.
In recent years, CAR-T cells have also emerged in the treatment of lymphoma.
With many advances in the field of lymphoma, you What new directions do you think are worth exploring in the future? Professor Zhu Jun has made great progress in the diagnosis and treatment of lymphoma in the past 20 years, and the cure rate of lymphoma patients has been significantly improved
.
Compared with other tumors, the survival rate and quality of life of patients with lymphoma have also been significantly improved
.
The progress in the diagnosis and treatment of lymphoma is mainly due to the development of precision therapy in recent years, including a series of breakthroughs in targeted therapy and immunotherapy
.
One of the most representative breakthroughs is the advent of anti-CD20 monoclonal antibodies.
The combination of anti-CD20 monoclonal antibodies and chemotherapy has significantly improved the efficacy of lymphoma, while promoting more monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates.
Came out
.
In addition, the advent of some small molecule drugs, such as immune checkpoint inhibitors and BTK inhibitors, has also brought significant improvements in the efficacy of lymphoma
.
In addition, in recent years, immunotherapy represented by chimeric antigen receptor T cells (CAR-T) has also achieved certain success in some lymphomas and leukemias
.
Many CAR-T therapies have been approved abroad for the treatment of lymphoma, and China has also recently approved two CAR-T therapies for the treatment of lymphoma
.
At present, many domestic centers are independently developing new CAR-T therapies, and at the same time trialing new CAR-T therapies in the clinic
.
The advent of many new drugs and new therapies has brought more options for the diagnosis and treatment of lymphoma
.
With the exploration of new drugs and new therapies in numerous clinical studies, the efficacy of lymphoma treatment is expected to be further improved in the future
.
"No chemotherapy" based on targeted therapy, immunotherapy, and cell therapy is expected to become an important treatment plan for lymphoma in the future, bringing better treatment options for the majority of lymphoma patients and providing more hope for cure
.
However, these new drugs and new therapies still have some limitations
.
Many new drugs and treatments are still not applicable to all patients with lymphoma
.
Some new drugs and new therapies have just been put on the market, and there are also problems with higher prices and lower accessibility
.
The diagnosis and treatment of lymphoma still has a long way to go
.
But I believe that through the joint efforts of our doctors and patients, these difficulties will eventually be overcome in the future and our diagnosis and treatment goals will be achieved
.
Patients with lymphoma will get a higher cure rate and a better quality of life
.
Yimaitong: How do you understand the theme of this year's World Lymphoma Awareness Day "WE CAN'T WAIT!"? Professor Zhu Jun's new crown epidemic has brought great changes and challenges to the diagnosis and treatment of lymphoma patients worldwide
.
But no matter what pressure and changes will be encountered in the diagnosis and treatment of lymphoma in the future, we all need to increase our confidence
.
No matter what difficulties we face, we have the confidence to get out of the predicament and meet the challenges
.
I think the theme of this year "WE CAN'T WAIT!" is to hope that we will continue to work hard and move forward courageously to overcome the difficulties in the diagnosis and treatment of lymphoma
.
Yimaitong: Doctors are not only treating tumors, but also taking care of patients throughout their life cycle
.
In your opinion, how should the humanistic care and communication of lymphoma patients be carried out during the diagnosis and treatment process? Professor Zhu Jun, both ancient and modern, Chinese and foreign, doctors need to have a benevolent heart
.
Only with a benevolent heart, our doctors can provide patients with warm services
.
No matter how advanced the diagnosis and treatment of lymphoma, how ambitious the treatment goal is, and how difficult the diagnosis and treatment process is, the most important thing for us as doctors is to provide patients with quality and warm services
.
In the process of diagnosis and treatment, we need to let patients feel the advancement of medical technology, feel the warmth of care among human beings, enhance patients' confidence in curing diseases, and help patients better overcome diseases
.
I think this is an eternal theme in the medical process
.
Professor Zhu Jun, Secretary of the Party Committee of Peking University Cancer Hospital, Director of the Department of Internal Medicine, and Doctoral Supervisor of the Director of the Lymphoma Department.
He mainly focuses on the diagnosis and treatment of malignant lymphoma.
Chairman of the Lymphoma Alliance Member of the Standing Committee of the Geriatric Oncology Committee of the Chinese Society of Gerontology, Member of the Standing Committee of the Chinese Anti-Cancer Association (CACA) of the Professional Committee of Cancer Targeted Therapy, Vice Chairman of the Beijing Anti-Cancer Association, Vice Chairman of the China Human Health Science and Technology Promotion Association, stamp "read the original text", We make progress together
.
According to statistics from the World Health Organization, the annual growth rate of lymphoma is 7.
5%, and it is currently one of the fastest-growing malignant tumors.
There are approximately 350,000 new cases worldwide each year
.
September 15, 2021 is the 18th "World Lymphoma Awareness Day"
.
On this occasion, Yimaitong had the honor to invite Professor Zhu Jun from Peking University Cancer Hospital to share the status quo and future development of lymphoma diagnosis and treatment in China
.
Yimaitong: Today we have ushered in the 18th "World Lymphoma Awareness Day".
What do you think of the rapid development of lymphoma diagnosis and treatment in my country in the past 18 years? Professor Zhu Jun has made great progress in the diagnosis and treatment of lymphoma in China in the past 18 years
.
First of all, clinicians in China have greatly improved their awareness of lymphoma, and standardized diagnosis and treatment have also been promoted nationwide
.
In the past, our understanding of different types of lymphomas was still lacking, but now with the widespread application of the internationally accepted WHO classification in the diagnosis of lymphomas, the misdiagnosis rate of lymphoma patients in China has been significantly improved
.
Secondly, the efficacy of lymphoma patients in China has also been greatly improved in the past 18 years
.
Taking the Lymphoma Department of Peking University Cancer Hospital as an example, the 5-year overall survival rate of lymphoma patients has increased by about 10%-15% in the past 18 years
.
At present, the 5-year overall survival rate of lymphoma patients in our department can reach more than 60%, and the 5-year overall survival rate of patients with classic Hodgkin’s lymphoma can reach 82%
.
This shows that the diagnosis and treatment level of lymphoma in China has improved significantly in the past 18 years
.
However, due to China's vast territory and uneven development in various regions, the 5-year overall survival rate of lymphoma patients nationwide is still at a low level in the world
.
To achieve the goal of cancer control in "Healthy China 2030", we need to increase the 5-year overall survival rate of lymphoma patients by at least 15% by 2030
.
This is both a pressure and a motivation
.
At present, there is still much room for improvement in the overall diagnosis and treatment of lymphoma in China.
The key to improving the diagnosis and treatment of lymphoma is to promote standardized diagnosis and treatment of lymphoma nationwide, strengthen multidisciplinary cooperation, and promote the development of lymphoma specialization.
Patients with multiple lymphomas can receive full health management and achieve an increase in the cure rate of lymphomas
.
Therefore, if we want to improve the 5-year overall survival of lymphoma patients, we still have a lot of work to do
.
Yimaitong: At present, China has made a lot of progress in the field of oncology
.
In order to further promote the development of standardized diagnosis and treatment of lymphoma, to achieve a 15% increase in the overall cancer 5-year survival rate as soon as possible, and to promote the implementation of the "Healthy China 2030 Plan", what actions or plans are currently in place? Do you have any suggestions for further planning in the future? Professor Zhu Jun First of all, I will start from myself, from our department and our center
.
By strengthening the standardized diagnosis and treatment of lymphoma and multidisciplinary cooperation, the lymphoma specialist team can develop better
.
Secondly, we also need to play the role of demonstration and lead, and better unite with colleagues across the country to promote standardized diagnosis and treatment of lymphoma and multidisciplinary cooperation
.
At present, the CSCO Anti-Lymphoma Expert Committee is an important platform.
We need to use this platform together with other different industry platforms across the country to help our colleagues across the country gain more relevant academic knowledge, so as to better promote the standardized diagnosis and treatment of lymphoma.
Disciplinary cooperation
.
Finally, at the level of national industry guidance, the expert committee established by us and the National Health Commission also needs to further promote the construction of lymphoma specialization across the country, improve the academic level of the specialized team, and promote it through more exchanges and learning.
Standardized diagnosis and treatment of lymphoma
.
I believe that as long as our colleagues across the country work together and work towards the goal of standardized diagnosis and treatment of lymphoma, we will definitely make substantial progress
.
Yimaitong: More than 20 years ago, the appearance of CD20 monoclonal antibody changed the treatment pattern of lymphoma.
In recent years, CAR-T cells have also emerged in the treatment of lymphoma.
With many advances in the field of lymphoma, you What new directions do you think are worth exploring in the future? Professor Zhu Jun has made great progress in the diagnosis and treatment of lymphoma in the past 20 years, and the cure rate of lymphoma patients has been significantly improved
.
Compared with other tumors, the survival rate and quality of life of patients with lymphoma have also been significantly improved
.
The progress in the diagnosis and treatment of lymphoma is mainly due to the development of precision therapy in recent years, including a series of breakthroughs in targeted therapy and immunotherapy
.
One of the most representative breakthroughs is the advent of anti-CD20 monoclonal antibodies.
The combination of anti-CD20 monoclonal antibodies and chemotherapy has significantly improved the efficacy of lymphoma, while promoting more monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates.
Came out
.
In addition, the advent of some small molecule drugs, such as immune checkpoint inhibitors and BTK inhibitors, has also brought significant improvements in the efficacy of lymphoma
.
In addition, in recent years, immunotherapy represented by chimeric antigen receptor T cells (CAR-T) has also achieved certain success in some lymphomas and leukemias
.
Many CAR-T therapies have been approved abroad for the treatment of lymphoma, and China has also recently approved two CAR-T therapies for the treatment of lymphoma
.
At present, many domestic centers are independently developing new CAR-T therapies, and at the same time trialing new CAR-T therapies in the clinic
.
The advent of many new drugs and new therapies has brought more options for the diagnosis and treatment of lymphoma
.
With the exploration of new drugs and new therapies in numerous clinical studies, the efficacy of lymphoma treatment is expected to be further improved in the future
.
"No chemotherapy" based on targeted therapy, immunotherapy, and cell therapy is expected to become an important treatment plan for lymphoma in the future, bringing better treatment options for the majority of lymphoma patients and providing more hope for cure
.
However, these new drugs and new therapies still have some limitations
.
Many new drugs and treatments are still not applicable to all patients with lymphoma
.
Some new drugs and new therapies have just been put on the market, and there are also problems with higher prices and lower accessibility
.
The diagnosis and treatment of lymphoma still has a long way to go
.
But I believe that through the joint efforts of our doctors and patients, these difficulties will eventually be overcome in the future and our diagnosis and treatment goals will be achieved
.
Patients with lymphoma will get a higher cure rate and a better quality of life
.
Yimaitong: How do you understand the theme of this year's World Lymphoma Awareness Day "WE CAN'T WAIT!"? Professor Zhu Jun's new crown epidemic has brought great changes and challenges to the diagnosis and treatment of lymphoma patients worldwide
.
But no matter what pressure and changes will be encountered in the diagnosis and treatment of lymphoma in the future, we all need to increase our confidence
.
No matter what difficulties we face, we have the confidence to get out of the predicament and meet the challenges
.
I think the theme of this year "WE CAN'T WAIT!" is to hope that we will continue to work hard and move forward courageously to overcome the difficulties in the diagnosis and treatment of lymphoma
.
Yimaitong: Doctors are not only treating tumors, but also taking care of patients throughout their life cycle
.
In your opinion, how should the humanistic care and communication of lymphoma patients be carried out during the diagnosis and treatment process? Professor Zhu Jun, both ancient and modern, Chinese and foreign, doctors need to have a benevolent heart
.
Only with a benevolent heart, our doctors can provide patients with warm services
.
No matter how advanced the diagnosis and treatment of lymphoma, how ambitious the treatment goal is, and how difficult the diagnosis and treatment process is, the most important thing for us as doctors is to provide patients with quality and warm services
.
In the process of diagnosis and treatment, we need to let patients feel the advancement of medical technology, feel the warmth of care among human beings, enhance patients' confidence in curing diseases, and help patients better overcome diseases
.
I think this is an eternal theme in the medical process
.
Professor Zhu Jun, Secretary of the Party Committee of Peking University Cancer Hospital, Director of the Department of Internal Medicine, and Doctoral Supervisor of the Director of the Lymphoma Department.
He mainly focuses on the diagnosis and treatment of malignant lymphoma.
Chairman of the Lymphoma Alliance Member of the Standing Committee of the Geriatric Oncology Committee of the Chinese Society of Gerontology, Member of the Standing Committee of the Chinese Anti-Cancer Association (CACA) of the Professional Committee of Cancer Targeted Therapy, Vice Chairman of the Beijing Anti-Cancer Association, Vice Chairman of the China Human Health Science and Technology Promotion Association, stamp "read the original text", We make progress together
